Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Placebo-Controlled Trial of Dapansutrile in Moderate COVID-19 With Early Cytokine Release Syndrome
2020-005227-37Phase 2Completed
- Sponsor
- Olatec Therapeutics LLC
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) comparing Dapansutrile with Placebo (2 arms). Primary endpoint: Complete resolution of fever-related symptoms and shortness of breath by Day 15. Started Dec 2020; status: completed.
02
Drugs
dapansutrile
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2020-005227-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005227-37.